<?xml version='1.0' encoding='utf-8'?>
<document id="25213162"><sentence text="A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin."><entity charOffset="19-31" id="DDI-PubMed.25213162.s1.e0" text="pantoprazole" /><entity charOffset="52-63" id="DDI-PubMed.25213162.s1.e1" text="doxorubicin" /><entity charOffset="175-186" id="DDI-PubMed.25213162.s1.e2" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.25213162.s1.e0" e2="DDI-PubMed.25213162.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25213162.s1.e0" e2="DDI-PubMed.25213162.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25213162.s1.e0" e2="DDI-PubMed.25213162.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25213162.s1.e1" e2="DDI-PubMed.25213162.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25213162.s1.e1" e2="DDI-PubMed.25213162.s1.e2" /></sentence><sentence text="In preclinical models, the proton pump inhibitor pantoprazole enhances the antitumor activity of chemotherapeutic agents by improving drug distribution and by inhibiting autophagy"><entity charOffset="49-61" id="DDI-PubMed.25213162.s2.e0" text="pantoprazole" /></sentence><sentence text="" /><sentence text="Patients with advanced solid tumors (n = 24) received doxorubicin 60 mg/m(2) and escalating doses of pantoprazole (80, 160, 240 and 360 mg) administered intravenously prior to doxorubicin"><entity charOffset="54-65" id="DDI-PubMed.25213162.s4.e0" text="doxorubicin" /><entity charOffset="101-113" id="DDI-PubMed.25213162.s4.e1" text="pantoprazole" /><entity charOffset="176-187" id="DDI-PubMed.25213162.s4.e2" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.25213162.s4.e0" e2="DDI-PubMed.25213162.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25213162.s4.e0" e2="DDI-PubMed.25213162.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25213162.s4.e0" e2="DDI-PubMed.25213162.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25213162.s4.e1" e2="DDI-PubMed.25213162.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25213162.s4.e1" e2="DDI-PubMed.25213162.s4.e2" /></sentence><sentence text=" Blood samples were collected for pharmacokinetic studies" /><sentence text=" An optional biopsy was performed to evaluate doxorubicin concentration and pharmacodynamic markers of drug activity"><entity charOffset="46-57" id="DDI-PubMed.25213162.s6.e0" text="doxorubicin" /></sentence><sentence text="" /><sentence text="Twenty-four patients participated in the study (17 in the dose escalation phase and 7 in the dose expansion)" /><sentence text=" Three patients experienced a dose limiting toxicity (grade 3 fatigue in the three cases), one patient at dose level 3 (pantoprazole 240 mg) and two patients at dose level 4 (pantoprazole 360 mg)"><entity charOffset="120-132" id="DDI-PubMed.25213162.s9.e0" text="pantoprazole" /><entity charOffset="175-187" id="DDI-PubMed.25213162.s9.e1" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.25213162.s9.e0" e2="DDI-PubMed.25213162.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25213162.s9.e0" e2="DDI-PubMed.25213162.s9.e1" /></sentence><sentence text=" Dose level 4 was considered to exceed the maximum tolerated dose" /><sentence text=" The recommended phase II dose was pantoprazole 240 mg and doxorubicin 60 mg/m(2)"><entity charOffset="35-47" id="DDI-PubMed.25213162.s11.e0" text="pantoprazole" /><entity charOffset="59-70" id="DDI-PubMed.25213162.s11.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.25213162.s11.e0" e2="DDI-PubMed.25213162.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25213162.s11.e0" e2="DDI-PubMed.25213162.s11.e1" /></sentence><sentence text=" The most commonly observed toxicities included fatigue, neutropenia and leukopenia" /><sentence text=" Two patients achieved a confirmed partial response" /><sentence text=" Median maximum serum concentration of pantoprazole was 84"><entity charOffset="39-51" id="DDI-PubMed.25213162.s14.e0" text="pantoprazole" /></sentence><sentence text="3 Î¼M at 1-2 h after injection of pantoprazole 240 mg"><entity charOffset="33-45" id="DDI-PubMed.25213162.s15.e0" text="pantoprazole" /></sentence><sentence text=" No drug-drug interaction was observed" /><sentence text=" A single on-treatment tumor biopsy showed a sharply decreasing gradient in doxorubicin concentration and associated activity markers with increasing distance from tumor blood vessels"><entity charOffset="76-87" id="DDI-PubMed.25213162.s17.e0" text="doxorubicin" /></sentence><sentence text="" /><sentence text="Administration of high doses of pantoprazole in combination with doxorubicin is feasible"><entity charOffset="32-44" id="DDI-PubMed.25213162.s19.e0" text="pantoprazole" /><entity charOffset="65-76" id="DDI-PubMed.25213162.s19.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.25213162.s19.e0" e2="DDI-PubMed.25213162.s19.e0" /><pair ddi="false" e1="DDI-PubMed.25213162.s19.e0" e2="DDI-PubMed.25213162.s19.e1" /></sentence><sentence text=" The recommended phase II dose of pantoprazole, 240 mg, will be evaluated in combination with docetaxel as first line in patients with castration-resistant prostate cancer"><entity charOffset="34-46" id="DDI-PubMed.25213162.s20.e0" text="pantoprazole" /><entity charOffset="94-103" id="DDI-PubMed.25213162.s20.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.25213162.s20.e0" e2="DDI-PubMed.25213162.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25213162.s20.e0" e2="DDI-PubMed.25213162.s20.e1" /></sentence><sentence text="" /></document>